Cigarette maker Philip Morris acquires another inhaled therapeutic ...
WEBAug 9, 2021 · The company last month agreed to acquire inhaled drug delivery technology developer Vectura for $1.2 billion — a move that was met by resistance from the American Lung Association. “The acquisition of OtiTopic is an exciting step in PMI’s Beyond Nicotine ambitions,” Philip Morris CEO Jacek Olczak said in the release.
Know Labs unveils wearable, non-invasive CGM set to go to FDA
WEBFeb 27, 2024 · A rendering of the KnowU non-invasive glucose monitor. [Image courtesy of Know Labs] Know Labs (NYSE:KNW) today unveiled KnowU, its wearable, non-invasive continuous glucose monitor (CGM) system. Seattle-based Know Labs first announced its initial prototype last June.It says KnowU is the result of an accelerated development process over the past eight months.
Kindeva Drug Delivery launches as independent company from 3M
WEBMay 4, 2020 By Danielle Kirsh. Kindeva Drug Delivery recently announced that it launched as an independent company, shedding its former 3M Drug Delivery Systems name. The formation of the independent company follows its acquisition by Altaris Capital Partners in a transaction that was worth $650 million. Through the acquisition, 3M will hold a ...
AMF Medical wins breakthrough nod for insulin management …
WEBNovember 30, 2021 By Sean Whooley. AMF Medical announced today that it received FDA breakthrough device designation for its Sigi insulin management system. Ecublens, Switzerland-based AMF Medical’s Sigi (for diabetes mellitus treatment) can be programmed to deliver basal and bolus insulin at both set and variable rates. Sigi, an alternate ...
Stevanato Group is constructing a new facility in Indiana
WEBOct 4, 2021 · Stevanato Group (NYSE:STVN) announced today that it will begin construction on a new U.S. facility in Fishers, Indiana. Piombino Dese, Italy-based Stevanato Group will begin construction on the new facility this month with expectations for the site to be operational in 2023. According to a …
Lilly plans rollout of Tempo diabetes management platform
WEBNov 9, 2022 · Lilly plans a phased rollout for the platform to select clinics starting later this year, followed by national availability targeted for 2023. In the EU, the Tempo Smart Button won a CE mark on August 10. Lilly plans to begin small-scale pilots in selected European countries through partnerships with existing diabetes management ecosystems.
West Pharma reveals new wearable SmartDose injectors
WEBNov 6, 2017 · West’s first-gen SmartDose device is a user-loaded injector designed to deliver high volumes of viscous drug products. Its SmartDose Gen. II device is a wearable system that can handle injection volumes of up to 10 mL and accommodates both glass and Daikyo crystal zenith containers. The company’s third-gen device is a pre-loaded version ...
Medtronic plans to bring next-gen diabetes tech to FDA this fiscal …
WEBNov 23, 2021 · The Medtronic MiniMed 780G system. [Image from Medtronic] Medtronic (NYSE:MDT) confirmed that it anticipates major regulatory steps for its next-generation insulin pump and sensor during this fiscal year. Medtronic’s fiscal years wrap up at the end of April. Speaking on the company’s second-quarter earnings call, Chair & CEO Geoff Martha said Medtronic expects its MiniMed 780G insulin pump ...
Study backs automated insulin delivery system from Diabeloop
WEBSeptember 21, 2022 By Sean Whooley. Diabeloop today announced 12-month data supporting its hybrid closed-loop DBLG1 automated insulin delivery system. Paris-based Diabeloop evaluated DBLG1 in a large, multi-country patient cohort. Results demonstrated constant improvement in time in range and time in hypoglycemia remaining significantly low.
MiMedx wins FDA regenerative med status for AmnioFix
WEBMarch 12, 2018 By Sarah Faulkner. MiMedx (NSDQ: MDXG) won regenerative medicine advanced therapy status from the FDA for its injectable osteoarthritis drug, AmnioFix, the company announced this week. The U.S. regulatory watchdog told MiMedx that the company provided sufficient preliminary evidence …